| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
§
From the Departments of Surgery*
and
Pathology,
Turku University Central Hospital,
Turku, the Department of Medical Biochemistry,
University of Turku, Turku, and the Department of
Anatomy,§
University of Oulu, Oulu, Finland
The NF1 gene product (neurofibromin) is known to act as a tumor suppressor protein by inactivating ras. The best documented factors involved in urinary bladder transitional cell carcinoma (TCC) are ras proto-oncogene activation and p53 suppressor gene mutations. This is the first study reporting alterations in NF1 gene expression in TCC. We examined NF1 gene expression in a total of 29 surgical urinary bladder TCC specimens representing grades 1 to 3 and in three cell lines, RT4, 5637, and T24 (representing grades 1 to 3, respectively). Decreased NF1 gene expression was observed in 23 of 29 (83%) TCC specimens as estimated by immunohistochemistry, the decrease being more pronounced in high-grade tumors. NF1 mRNA levels were markedly lower in TCC tissue compared with adjacent non-neoplastic urothelium, as studied by in situ hybridization for grade 3 TCC. Immunohistochemistry and Western blotting demonstrated that TCC cell lines expressed NF1 protein at different levels, expression being almost undetectable in T24 (grade 3) cells. Northern blotting for cell lines demonstrated reduced NF1 mRNA levels in grade 3 TCC cells. Reverse transcription polymerase chain reaction for cell lines and selected grade 2 and grade 3 tissue samples demonstrated NF1 type II mRNA isoform predominance in all samples studied. Our results show that both NF1 mRNA and protein levels are decreased in high-grade TCC, suggesting that alterations of NF1 gene expression may be involved in bladder TCC carcinogenesis.
This article has been cited by other articles:
 |
|
 |
|
  H. Chen, Y. Qiu, L. Chen, L. Li, J. Chen, C. Zhang, B. Wang, Y. Yu, Z. Zhu, F. Zhu, et al. The Expression of Neurofibromin in Human Osteoblasts and Chondrocytes Ann. Clin. Lab. Sci., January 1, 2008; 38(1): 25 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Cacev, S Radosevic, R Spaventi, K Pavelic, and S Kapitanovic NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer Gut, August 1, 2005; 54(8): 1129 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. Junttila, M. Laato, T. Vahlberg, K.-O. Soderstrom, T. Visakorpi, J. Isola, and K. Elenius Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients Clin. Cancer Res., November 1, 2003; 9(14): 5346 - 5357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Karashima, P. Sweeney, A. Kamat, S. Huang, S. J. Kim, M. Bar-Eli, D. J. McConkey, and C. P. N. Dinney Nuclear Factor-{kappa}B Mediates Angiogenesis and Metastasis of Human Bladder Cancer through the Regulation of Interleukin-8 Clin. Cancer Res., July 1, 2003; 9(7): 2786 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-L. Karvonen, M. Kallioinen, H. Yla-Outinen, M. Poyhonen, A. Oikarinen, and J. Peltonen Occult Neurofibroma and Increased S100 Protein in the Skin of Patients With Neurofibromatosis Type 1: New Insight to the Etiopathomechanism of Neurofibromas Arch Dermatol, October 1, 2000; 136(10): 1207 - 1209. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
